Please assess the completion status of the following clinical trial:

Trial Title: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* Histologically confirmed (according to the WHO classification) diffuse large B-cell lymphoma stage II-IV~* No previous treatment for lymphoma. Corticosteroids for alleviation of lymphoma associated symptoms are allowed~* WHO performance status 0-2~* HIV negativity~* Seronegativity for HCV, HBsAg, anti-HBc, or other active infection uncontrolled by treatment~* Absence of psychiatric illness or condition which could interfere with the subjects ability understand the requirements of the study~* Absence of neurological or neuropsychiatric disorder, interfering with the requirements of the study~* Absence of hearing impairment \> grade 2~* Absence of porphyria~* In females: absence of pregnancy and lactation~* All subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy~* All subjects must agree not to share study medication with another person, and to return all unused study drug to investigators~* Written informed concent according to ICH/GCP and Swedish regulations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Single, open labeld. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).